Abstract
The subclassification of α- and β-adrenoceptors has resulted in many opportunities for drug discovery. Important adrenoceptor targets include β2-agonists as bronchodilators, β1 or β1/β2 antagonists as antihypertensives, centrally acting α2-agonists for a variety of applications and α1-antagonists for hypertension and benign prostatic hyperplasia. The pharmacology and nomenclature of 9 adrenoceptors is now established, with α1, α2 and β-adrenoceptors being divided into three subtypes each. It is unlikely that additional discrete adrenoceptor sequences will be identified; however the presence of “affinity states” can give rise to tissue specific differences in pharmacology for a specific subtype. Polymorphisms and splice variants of adrenoceptors continue to be identified; in some cases these modifications can affect pharmacological characteristics and could influence the efficacy of adrenoceptor-targeted therapy. Selective antagonists are now available of all 9 adrenoceptor subtypes. Although these will not all have therapeutic application, the availability of improved pharmacologic tools could lead to the identification of new adrenoceptor targets.
Keywords: Uroselectivity, receptor polymorphism, splice variant, α1L-adrenoceptor, β4-adrenoceptor
Current Topics in Medicinal Chemistry
Title: Subclassification and Nomenclature of α- and β-Adrenoceptors
Volume: 7 Issue: 2
Author(s): J. Paul Hieble
Affiliation:
Keywords: Uroselectivity, receptor polymorphism, splice variant, α1L-adrenoceptor, β4-adrenoceptor
Abstract: The subclassification of α- and β-adrenoceptors has resulted in many opportunities for drug discovery. Important adrenoceptor targets include β2-agonists as bronchodilators, β1 or β1/β2 antagonists as antihypertensives, centrally acting α2-agonists for a variety of applications and α1-antagonists for hypertension and benign prostatic hyperplasia. The pharmacology and nomenclature of 9 adrenoceptors is now established, with α1, α2 and β-adrenoceptors being divided into three subtypes each. It is unlikely that additional discrete adrenoceptor sequences will be identified; however the presence of “affinity states” can give rise to tissue specific differences in pharmacology for a specific subtype. Polymorphisms and splice variants of adrenoceptors continue to be identified; in some cases these modifications can affect pharmacological characteristics and could influence the efficacy of adrenoceptor-targeted therapy. Selective antagonists are now available of all 9 adrenoceptor subtypes. Although these will not all have therapeutic application, the availability of improved pharmacologic tools could lead to the identification of new adrenoceptor targets.
Export Options
About this article
Cite this article as:
Hieble J. Paul, Subclassification and Nomenclature of α- and β-Adrenoceptors, Current Topics in Medicinal Chemistry 2007; 7 (2) . https://dx.doi.org/10.2174/156802607779318172
DOI https://dx.doi.org/10.2174/156802607779318172 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Improving Patient Compliance with Hypertension Treatment: Mission Possible?
Current Vascular Pharmacology Pharmacological Management of Hypertension in the Elderly - Certitudes and Controversies
Current Pharmaceutical Design Egg Proteins and Peptides in Human Health-Chemistry, Bioactivity and Production
Current Pharmaceutical Design Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Current Neuropharmacology The Relevance of New Drug Combinations for Modern Tuberculosis Treatment - A Patent Perspective
Recent Patents on Anti-Infective Drug Discovery Beneficial Effect of Peptides from Microalgae on Anticancer
Current Protein & Peptide Science A Murine Model of Vasculitis Induced by Fungal Polysaccharide
Cardiovascular & Hematological Agents in Medicinal Chemistry Inhibition of RAGE Axis Signaling: A Pharmacological Challenge
Current Drug Targets CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design The “Parkinsonian Heart”: From Novel Vistas to Advanced Therapeutic Approaches in Parkinsons Disease
Current Medicinal Chemistry Fluoroquinolones: Blessings Or Curses
Current Drug Targets Three-Dimensional Ultrasound in Fetal Size and Growth Assessment
Current Medical Imaging Editorial [Chronic Thromboembolic Pulmonary Hypertension-Therapeutic Options]
Current Respiratory Medicine Reviews Neuroprotection by (endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases
Current Neuropharmacology Bioorganic Compounds Produced by the Fungus Monascus and their Use in Health Sciences and Medicine
Mini-Reviews in Organic Chemistry Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease
Current Medicinal Chemistry Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design Lead (Pb) in Alzheimer’s Dementia: A Systematic Review of Human Case- Control Studies
Current Alzheimer Research Editorial [Hot topic: Adenosine Receptor Ligands: Where Are We, and Where Are We Going? (Guest Editors: Tiziano Tuccinardi and Adriano Martinelli)]
Current Topics in Medicinal Chemistry